Poxel is Looking towards Japan’s Lucrative Diabetes Market


Sign up online today & collaborate

or click here to find out more

Poxel is Looking towards Japan’s Lucrative Diabetes Market


Date: 29/05/2015

Poxel, the French company that made a €27M IPO last February,  announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III.

This innovative compound is the first of a new class of oral antidiabetic agents called “glimins“. It basically decreases mitcohondrial respiration, meaning that it targets the key defect associated with all three organs implicated in type II diabetes. Clinical studies to date have proven Imeglimin to have an efficiency comparable to Metformin, the golden standard treatment. Imeglimin, however, has a better safety/tolerability profile and doesn’t induce patient resistance, which Metformin unfortunately does.

For more click here

source: Labiotech

© Catalyst Innovation Portal 2019